The global benign prostatic hyperplasia treatment market is estimated to witness significant growth during the forecast period. The rising demand for innovative treatment options for benign prostatic hyperplasia is driving the market growth. 5 alpha-reductase inhibitors are the new innovation in benign prostatic hyperplasia drug treatment market. This helps to treat the lower urinary tract. further, artery embolization is the new innovation in minimally invasive procedure alternatives to surgery for benign prostatic hyperplasia treatment. This procedure is less costly and less painful, with no hospital stay. Transurethral resection of the prostate (TURP) is one of the innovation in the minimally invasive procedure, this was developed by the surgical urology team at Penn State Health Milton S. Hershey Medical Center. Rezum, a minimally invasive technology one of the innovations in this field for the treatment of benign prostatic hyperplasia. Rezum is used for prostate volumes greater than 30 cm3.

A full Report of Global Benign Prostatic Hyperplasia Treatment Market at https://www.omrglobal.com/industry-reports/benign-prostatic-hyperplasia-treatment-market

Due to the very low-risk rate, prostatic hyperplasia patients are moving towards laser therapy/surgeries. For patients with moderate or large prostates often prefer laser surgery. Some of the innovations in the laser surgeries are holmium and Photoselective Vaporization of the Prostate (PVP), Holmium Laser Enucleation of the Prostate (HoLEP), and others. Photoselective Vaporization of the Prostate (PVP) is also known as “Greenlight laser”. This is a minimally invasive technique, it uses high-powered laser light to vaporize the overgrowth of prostate cells. Holmium Laser Enucleation of the Prostate (HoLEP), this laser surgery used to remove the blockages of urine flow, this procedure is done without any cut in the body.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/benign-prostatic-hyperplasia-treatment-market

Global Benign Prostatic Hyperplasia Treatment Market Segmentation

Types of Treatment

• Medications
• Alpha-blockers
• 5 Alpha reductase inhibitor (ARIs)
• Phosphodiesterase-5 Enzyme Inhibitor
• Others

Minimally Invasive Procedures

• Transurethral Resection of the Prostate (TURP)
• Transurethral Incision of the Prostate (TUIP)
• Transurethral Microwave Thermotherapy (TUMT)
• Transurethral Needle Ablation (TUNA)
• Laser Therapy
• Ablative procedures
• Enucleation procedures
• Others

Global Benign Prostatic Hyperplasia Treatment Market – Segment by Region

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

Company Profiles

• Abbott Laboratories
• Allergan, Inc.
• Astellas Pharma, Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corp.
• Camber Pharmaceuticals, Inc.
• Coloplast A/S
• Daiichi Sankyo Co., Ltd.
• Eli Lilly &Co.
• Endo International PLC
• GlaxoSmithKline PLC
• Karl Storz GmbH& Co.Kg
• Lumenis, Ltd.
• Merck & Co., Inc.
• Nymox Pharmaceutical Corp.
• Olympus Corp.
• Pfizer, Inc.
• ProArc Medical, Ltd.
• Sanofi S.A.
• Sophiris Bio Corp.
• Sun Pharmaceutical Industries, Ltd.
• Synthon B.V.
• Teva Pharmaceutical Industries, Ltd.
• Urologix, Inc.
• Veru, Inc.


For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/benign-prostatic-hyperplasia-treatment-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404